CN108114228A - A kind of Chinese medicine composition for treating diabete and preparation method thereof - Google Patents

A kind of Chinese medicine composition for treating diabete and preparation method thereof Download PDF

Info

Publication number
CN108114228A
CN108114228A CN201711378204.9A CN201711378204A CN108114228A CN 108114228 A CN108114228 A CN 108114228A CN 201711378204 A CN201711378204 A CN 201711378204A CN 108114228 A CN108114228 A CN 108114228A
Authority
CN
China
Prior art keywords
parts
radix
chinese medicine
medicine composition
pill
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711378204.9A
Other languages
Chinese (zh)
Inventor
王小官
曾勇
王凤英
皮丽芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUANGGANG-CITY HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Original Assignee
HUANGGANG-CITY HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUANGGANG-CITY HOSPITAL OF TRADITIONAL CHINESE MEDICINE filed Critical HUANGGANG-CITY HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Publication of CN108114228A publication Critical patent/CN108114228A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9064Amomum, e.g. round cardamom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/57Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232Angelica
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/346Platycodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/40Cornaceae (Dogwood family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488Pueraria (kudzu)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/57Magnoliaceae (Magnolia family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/79Schisandraceae (Schisandra family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968Ophiopogon (Lilyturf)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a kind of Chinese medicine composition for treating diabete and preparation method thereof, Chinese medicine composition includes 10 parts of Radix Rehmanniae, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, 5 parts of Radix Glehniae, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae, 5 parts of gypsum;Guiding drug is used to treat in diabete compound for the first time by the present invention;The present invention can effectively reduce empty stomach, postprandial blood sugar, glycosylated hemoglobin, and it can lose weight to a certain extent, improve islet function and insulin resistance, have a better role to the insulin resistance tool of diabetes B patient (syndrome of deficiency of both qi and yin);It is especially acted in terms of the clinical symptoms such as dry, more drink, diuresis are improved notable;Mitigate the side effect of oral hypoglycemic agents, prevention liver and kidney dysfunction, hypoglycemia occur;The quality of life of patient is improved, reduces complex treatment expense.

Description

A kind of Chinese medicine composition for treating diabete and preparation method thereof
Technical field
The present invention relates to field of medicaments, more particularly, to a kind of Chinese medicine composition for treating diabete and preparation method thereof.
Background technology
Diabete is similar to the diabetes of modern medicine, it is a kind of closely related with the factors such as hereditary, immune, environment Disease, even more threaten health of people common disease, frequently-occurring disease.With the formation of aging society, industrialized quick hair Exhibition, people's eating habit, fast pace, strong competition, more move less, take a bus instead of walking living-pattern preservation, result in diabetes Incidence rapidly increases.The data of the World Health Organization shows, about 30,000,000 diabetic of the whole world in 1985, to 1997 Year surges to 1.35 hundred million;Global diabetes B illness number is 1.5 hundred million within 2000.China diabetic is in 95,000,000 people at present More than, and age of onset increasingly rejuvenation.It is mainly diabetes B, that is, non-pancreas in the diabetic sharply increased in quantity Island element dependent diabetes mellitus, accounts for more than the 95% of patient populations.
Illness rate, disability rate and the death rate of diabetes and total health hazard degree occupy the 3rd of non-communicable diseases Position, is the third-largest killer for being only second to cardiovascular and cerebrovascular disease and tumour in China.Diabetic suffers from ischemic angiocardiopathy and cerebrovascular disease Disease, limb necrosis, renal failure and that loses the sight of both eyes dangerous be higher by several times even more than 20 times than normal person.This sick acute and chronic Complication harm is big, scope is wide.
In terms of the treatment of diabetes, western modern medicine has its unique advantage, it rapidly and efficiently unquestionable.But such as What reduces the side effect for the treatment of medication up to the present there are no new breakthrough, and prevention in diabetes, treatment diabetes Complication in terms of, have that its is clearly disadvantageous.And the peculiar effect of traditional Chinese medicine in this respect, and his toxic side effect is small, treats Effect is apparent, has obtained Hesperian accreditation at present.Syndrome of deficiency of both qi and yin accounts for more than 80% in diabetes, to syndrome of deficiency of both qi and yin With side research have particularly important meaning.
The external research to diabetes at present, focuses on molecular biology, gene, stem cell etc..Although the world is each State has put into huge manpower, financial resources, but makes slow progress.Medication study is only the optimization on the basis of five class medicines, and no matter flies Jump.With the popularization of traditional Chinese medicine technology in the world, curative effect obtains being widely recognized as countries in the world, and accordingly Chinese medicine is treated The research of diabetes is also subject to west various countries to gaze at.It is investigated that readding current paper, the clinic of TCM Treatment of Diabetes is ground by foreign countries Study carefully at present also in initial period.Due to the abstractness of theory of traditional Chinese medical science, globality, the otherness of Chinese and Western culture, academic exchange translation Uncertainty, foreign countries be to the research of traditional Chinese medicine according to evidence-based medicine EBM pattern progress, run counter to traditional Chinese medical science organic conception completely Under individual difference, therefore external research is not also the Chinese medicine study in complete meaning.
The clinical research of domestic TCM Treatment of Diabetes and its complication:It is less to the study of compound prescription of traditional Chinese medicine, digit It is less for the study of compound prescription of diabetes mellitus prevention, treatment in terms of being diabetic complication mostly in limited research.But The research of Chinese medicine, prevention diabetes and its complication all achieves gratifying achievement.But studies in China or only Clinical observation has only been done, has been studied without positive control;Or only using doctor trained in Western medicine Specifications as evaluation criterion, do not have There is the diagnosis and treatment based on an overall analysis of the illness and the patient's condition theory for adopting traditional Chinese medicine to go to instruct;Or prescription forms and compatibility theory is different from we;In either Medicine compound includes western medicine composition;Or without biochemical indicator, safety research.Or without complete fasting blood-glucose, postprandial 2 Hour blood glucose, glycosylated hemoglobin comparative study.
The content of the invention
To solve the above problems, the present invention proposes a kind of Chinese medicine composition for treating diabete and preparation method thereof.
The technical scheme is that:A kind of Chinese medicine composition for treating diabete includes the raw material of following parts by weight Medicine:1-20 parts of Radix Rehmanniae, 1-20 parts of pueraria lobata, 1-20 parts of Fructus Corni, 1-20 parts of Radix Astragali, Radix Ophiopogonis 1-10 part, 1-10 parts of Poria cocos, north are husky 1-10 parts of ginseng, 1-10 parts of kadsura longepedunculata, 1-10 parts of dried orange peel, 1-10 parts of fructus amomi, 1-10 parts of Radix Angelicae Sinensis, 1-10 parts of the membrane of a chicken's gizzard, campanulaceae 1- 10 parts, 1-10 parts of gypsum.
Further, a kind of Chinese medicine composition for treating diabete, the parts by weight of each raw material are:10 parts of Radix Rehmanniae, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, 5 parts of Radix Glehniae, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae, 5 parts of gypsum.
Further, a kind of Chinese medicine composition for treating diabete, can be according to conventional method of Chinese medicinal system The standby oral formulations into any routine.
Further, the Radix Glehniae, kadsura longepedunculata can use red ginseng 10g, fructus schisandrae 10g to substitute.
Further, oral formulations are that the preparation is pill, capsule, tablet, powder, granule or oral agents.
Further, the arbitrary Chinese medicine composition is preparing the application in treating medicine of quenching one's thirst.
A kind of preparation method for the Chinese medicine composition for treating diabete, includes the following steps:
Step 1:Take 10 parts of the Radix Rehmanniae of parts by weight, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, Poria cocos 5 Part, 5 parts of Radix Glehniae, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae are respectively put into heat Wind cycle baking oven in, with 80 DEG C baking 6 it is small when.
Step 2:It crushes, 5 parts of dried drug in step 1 and gypsum is crushed respectively with pulverizer.
Step 3:The medicinal powder crushed is crossed 80 mesh sieves by sieving respectively;
Step 4:Mixing, medicinal powder is uniformly mixed.
Step 5:Molding;
Step 6:Pill, with general preparation method pill;
Step 7:Polishing, until pill surface is smooth consistent.
Step 8:It is dry, pill is uniformly put into heated-air circulation oven, is toasted with 80 DEG C, until dry complete;
Step 9:Ball is selected, underproof pill is picked and is selected;
Step 10:It is filling, qualified pill is dispensed into packaging successively.
The solution have the advantages that:
(1) new drug is provided for diabete (syndrome of deficiency of both qi and yin) patient's Chinese traditional treatment.
(2) effective auxiliary is provided for the dialectical patient for diabete (syndrome of deficiency of both qi and yin) of diabetic's traditional Chinese medical science differentiation of disease Medication, so as to mitigate the side effect of Western medicine, stablize hypoglycemic, improvement patients ' life quality, extension patient's service life.
(3) optimize the compatibility of medicines in a prescription, reduce patient medical expense.
Specific embodiment
With reference to reference to the technical program is further described, the example of the embodiment is shown in, wherein from beginning extremely Same or similar label represents same or similar element or has the function of same or like element eventually, but the description is only For explaining the present invention, and it is not considered as limiting the invention.
First, embodiment:
Embodiment 1:The preparation of capsule.
Take 10 parts of the Radix Rehmanniae of parts by weight, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, north sand 5 parts of ginseng, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae, 5 parts of gypsum.
The mixture of above-mentioned each component with pulverizer is crushed respectively, is filled after the medicinal powder crushed is crossed 80 mesh sieves respectively Enter capsule.
Embodiment 2:The preparation of granule.
Take 10 parts of the Radix Rehmanniae of parts by weight, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, north sand 5 parts of ginseng, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae, 5 parts of gypsum.
The mixture of above-mentioned each component with pulverizer is crushed respectively, after the medicinal powder crushed is crossed 80 mesh sieves respectively, is added Enter ethyl alcohol and make binder, add in starch and do filler, be pressed into granule.
Embodiment 3:The preparation of tablet.
Take 10 parts of the Radix Rehmanniae of parts by weight, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, north sand 5 parts of ginseng, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae, 5 parts of gypsum.
The mixture of above-mentioned each component is crushed respectively with pulverizer, after the medicinal powder crushed is crossed 80 mesh sieves respectively, system Piece agent.
Embodiment 4:The preparation of pill.
Take 10 parts of the Radix Rehmanniae of parts by weight, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, north sand 5 parts of ginseng, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae are respectively put into hot air circulation In baking oven, with 80 DEG C baking 6 it is small when.
Step 2:It crushes, 5 parts of dried drug in step 1 and gypsum is crushed respectively with pulverizer.
Step 3:The medicinal powder crushed is crossed 80 mesh sieves by sieving respectively;
Step 4:Mixing, medicinal powder is uniformly mixed.
Step 5:Molding;
Step 6:Pill, with general preparation method pill;
Step 7:Polishing, until pill surface is smooth consistent.
Step 8:It is dry, pill is uniformly put into heated-air circulation oven, is toasted with 80 DEG C, until dry complete;
Step 9:Ball is selected, underproof pill is picked and is selected;
Step 10:It is filling, qualified pill is dispensed into packaging successively.
Embodiment 5:The preparation of oral liquid.
Take 10 parts of the Radix Rehmanniae of parts by weight, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, north sand 5 parts of ginseng, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae, 5 parts of gypsum.
The mixture of above-mentioned each component is mixed, after filtering boil three times, is concentrated into normal concentration, embedding cools down, sterilizing, Oral liquid is packaged into after inspection.
2nd, experimental example:
72 diabetes (syndrome of deficiency of both qi and yin) of clinical observation meet the case of inclusion criteria, in December, 2013 to 2015 June in year, the age was between 34-75 Sui in Huanggang-City Hospital of Traditional Chinese Medicine out-patient, wherein man 33, female 39;Average height 165cm;Average weight 53.9kg;Average course of disease 5.2 years;Basic, normal, high dosage present invention system is randomly divided into according to medical order Agent group and existing diabetes pill control group, every group each 18.The age of four groups of patients, gender, height, weight, the course of disease, traditional Chinese medical science disease Scoring is waited to be comparable without significant difference (P > 0.05).
Diagnostic criteria:Meet the diabetes diagnostic criterion of WHO in 1999, Chinese medical discrimination is diabete syndrome of deficiency of both qi and yin person. (reference《New Chinese medicine guideline of clinical investigations》)
Inclusion criteria:20 years old≤age≤65 year old, men and women was unlimited.Informed consent voluntarily coordinates this research, in accordance with this Invent the scheme that seminar formulates.
Exclusion criteria:1. the prediabetes caused by drug or chemicals, such as:Dilantin sodium, glucocorticoid are done After disturbing plain α treatments;2. severe systemic disease;3. hormone etc. was used to influence the drug of glycometabolism in 3 months;4. pregnant woman, standard Standby gestation and the women of nursing period.
Therapy
Implement according to the diet program of diabetes routine, using the medicament prepared by the embodiment of the present invention, usage and dosage is such as Under:
1) capsule:Three times a day, each taking 2~4, every 0.5 gram of content of dispersion, warm water takes.
2) tablet:Three times a day, every time 2~4, every 0.5 gram of content of dispersion, warm water takes.
3) pill:Three times a day, basic, normal, high dosage invention formulation group is for oral use after daily breakfast, lunch and dinner, 5g, 10g, 15g.Warm water takes.
4) granule:Three times a day.Basic, normal, high dosage invention formulation group is for oral use after daily breakfast, lunch and dinner, 5g, 10g, 15g.Warm water takes.
Above-mentioned pill, granule, oral liquid, capsule, tablet are respectively in basic, normal, high dosage invention formulation group During experiment, active constituent content is identical.
Control group:Diabetes pill (Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd.) control group (without Western medicine is used) is in daily three Diabetes pill 10 is taken after the meal, two groups of courses for the treatment of are 10 weeks.
Observation index
Security observation index:General physical examination project;Blood, urine, stool routine+occult blood;Hepatic and renal function.
Health giving quality observation index:
The evaluation of lab index:Compare each group patient the 0th, 2,6,10 week fasting blood-glucose (FBG), postprandial 2 after the treatment The variation of hour blood glucose (2hPG) and glycosylated hemoglobin (HbA1c), the effect of evaluation control blood glucose.
The evaluation of tcm symptom index:Diuresis, polyorexia mostly are drunk to patient, body is become thin, fatigue and asthenia, dysphoria with smothery sensation sweat Go out, the red few TCM syndromes such as tongue, the thready rapid pulse scoring of tongue carries out evaluation analysis.
TCM syndrome integration is shown in Table one:
Table one is diabete TCM symptom score method
Criterion of therapeutical effect
With reference to Chinese Medical Association《Diabetes TCM prevention and cure guide》.Diabetes curative effect judgement includes curative effect of disease and judges mark Accurate, leading indicator curative effect (i.e. hypoglycemic curative effect) evaluation and card marquis's curative effect determinate standard.
Curative effect of disease criterion
It is effective:Tcm clinical practice symptom, sign are obviously improved, and card Hou Jifen reduces >=70%;Fasting blood-glucose and postprandial 2 small When blood glucose drop to normal range (NR) or fasting blood-glucose and 2 it is small when blood glucose value decrease beyond treatment before 40%, HbAle egg White value drops to less than 6.2% or decrease beyond before treatment 30%.
Effectively:Tcm clinical practice symptom, sign take a favorable turn, and card Hou Jifen reduces >=30%;Fasting blood-glucose and postprandial 2 small When blood glucose decrease beyond before treatment 20%, but not up to effective standard, before glycosylated hemoglobin value decrease beyond treatment 10%, but not up to effective standard.
It is invalid:Tcm clinical practice symptom, sign are not improved, even aggravating, card Hou Jifen is reduced less than 30%:It is empty Abdomen blood glucose and it is postprandial 2 it is small when blood glucose without decline or decline be not up to effective standard, glycosylated hemoglobin value without decline or decline Not up to effective standard.
Predominantly detect index (blood glucose) curative effect determinate standard
It is effective:Fasting blood-glucose and it is postprandial 2 it is small when blood glucose drop to normal range (NR) or fasting blood-glucose and it is postprandial 2 it is small when blood glucose 40% decrease beyond before treatment, glycosylated hemoglobin value drop to normally or decrease beyond 30% before treatment.
Effectively:Fasting blood-glucose and it is postprandial 2 it is small when blood glucose decrease beyond before treatment 20%, but not up to effective standard, sugar Change Hemoglobin Value is decrease beyond before treatment 10%, but not up to effective standard.
It is invalid:Fasting blood-glucose and it is postprandial 2 it is small when blood glucose without decline or decline be not up to effective standard, glycosylated hemoglobin Value is without decline or declines not up to effective standard.
Note:Fasting blood-glucose, it is postprandial 2 it is small when blood glucose should carry out curative effect evaluation respectively.
Syndrome in TCM marquis's efficacy determination method
It is effective:Clinical symptoms, sign are obviously improved, and integration reduces >=70%.
Effectively:Clinical symptoms, sign take a favorable turn, and integration reduces >=30%.
It is invalid:Clinical symptoms, sign are not improved, even aggravating, integration is reduced less than 30%.
It is calculated according to Nimodipine method:Therapeutic index (n)=[product divides ﹚ ÷ to be integrated before treating after integration-treatment before ﹙ is treated] × 100%.
The statistical method that the present invention uses is general-purpose computations side of the State Administration of Traditional Chinese Medicines on clinical research efficacy determination Method.
Statistical analysis is carried out to data with SPSS17.0 softwares, measurement data is with mean ± standard deviationIt represents, P<0.05 is statistically significant for difference.P values refer to probability, the possibility size that reflection event occurs.Statistics is according to conspicuousness The obtained P values of the method for inspection are generally notable with P < 0.05.It is meant that the difference between sample is general caused by sampling error Rate is small.
Following table 1- tables 4 are the comparisons of each group pretherapy and post-treatment different time points FBG, 2hPG, HbA1c.
The comparison of 1 each treatment group of table different time points FBG (mmolL-1) after the treatment
* the P compared with before treatment<0.05;# P > 0.05 compared with the 10th week other groups
1 result of table:* the 2nd, 6,10 week fasting blood-glucose and treatment after low dosage, middle dosage, high dose, the treatment of diabetes pill group It is preceding compared to evident in efficacy, inter-sample difference has statistical significance.
10th week sky after the 10th week fasting blood-glucose and diabetes pill group are treated after # low dosages, middle dosage, the treatment of high dose group Abdomen blood glucose compares therapeutic equivalence, and inter-sample difference is not statistically significant.
The comparison of 2 each group of table different time points 2hPG (mmolL-1) after the treatment
* the P compared with before treatment<0.05;# P > 0.05 compared with the 10th week other groups
2 result of table:* low dosage, middle dosage, high dose, diabetes pill group treatment after the 2nd, 6,10 week it is postprandial 2 it is small when blood glucose Evident in efficacy compared with pre-treatment, inter-sample difference has statistical significance.
# low dosages, middle dosage, high dose group treatment after the 10th week it is postprandial 2 it is small when blood glucose and diabetes pill group treat after the 10th Blood glucose compares therapeutic equivalence when week postprandial 2 is small, and inter-sample difference is not statistically significant.
The comparison of 3 each group of table different time points HbA1c (%) after the treatment
* the P compared with before treatment<0.05;# P > 0.05 compared with the 10th week other groups
3 result of table:* the 10th week glycosylated hemoglobin and treatment after low dosage, middle dosage, high dose, the treatment of diabetes pill group It is preceding compared to evident in efficacy, inter-sample difference has statistical significance.
The 10th after the 10th week glycosylated hemoglobin and diabetes pill group are treated after # low dosages, middle dosage, the treatment of high dose group All glycosylated hemoglobins compare therapeutic equivalence, and inter-sample difference is not statistically significant.
Curative effect of disease compares (example) 4 each group of table after the treatment
* the P > 0.05 compared with diabetes pill group
4 result of table:* low dosage, middle dosage, high dose group treatment after the 10th week with diabetes pill group treatment after the 10th week always Efficient suitable, inter-sample difference has statistical significance.
The 10th after the 10th week glycosylated hemoglobin and diabetes pill group are treated after # low dosages, middle dosage, the treatment of high dose group All glycosylated hemoglobins compare therapeutic equivalence, and inter-sample difference is not statistically significant.
The evaluation of tcm symptom index
Basic, normal, high dosage invention formulation and diabetes pill can improve deficiency of both qi and yin and quench one's thirst more drink diuresis of patient, Polyorexia, body are become thin, fatigue and asthenia, the clinical symptoms such as dysphoria with smothery sensation sweating, improve the quality of life of diabetic.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned exemplary embodiment, Er Qie In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, nothing By from the point of view of which point, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by institute Attached claim rather than above description limit, it is intended that will fall within the meaning and scope of the equivalent requirements of the claims All changes be included within the present invention.
Moreover, it will be appreciated that although this specification is described in terms of embodiments, but not each embodiment is only Comprising an independent technical solution, this description of the specification is merely for the sake of clarity, and those skilled in the art should When using specification as an entirety, the technical solutions in each embodiment can also be properly combined, forms people in the art The other embodiment that member is appreciated that.

Claims (7)

1. a kind of Chinese medicine composition for treating diabete, which is characterized in that include the bulk pharmaceutical chemicals of following parts by weight:Radix Rehmanniae 1-20 Part, 1-20 parts of pueraria lobata, 1-20 parts of Fructus Corni, 1-20 parts of Radix Astragali, Radix Ophiopogonis 1-10 part, 1-10 parts of Poria cocos, 1-10 parts of Radix Glehniae, south five 1-10 parts of taste, 1-10 parts of dried orange peel, 1-10 parts of fructus amomi, 1-10 parts of Radix Angelicae Sinensis, 1-10 parts of the membrane of a chicken's gizzard, 1-10 parts of campanulaceae, gypsum 1- 10 parts.
A kind of 2. Chinese medicine composition for treating diabete according to claim 1, which is characterized in that the parts by weight of each raw material It is:10 parts of Radix Rehmanniae, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, 5 parts of Radix Glehniae, kadsura longepedunculata 5 Part, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae, 5 parts of gypsum.
3. according to a kind of any Chinese medicine composition for treating diabete of claim 1 or 2, which is characterized in that described Radix Glehniae, kadsura longepedunculata can use red ginseng 10g, fructus schisandrae 10g to substitute.
4. according to a kind of any Chinese medicine composition for treating diabete of claim 1 or 2, which is characterized in that can be according to Conventional method of Chinese medicinal is prepared into the oral formulations of any routine.
5. a kind of Chinese medicine composition for treating diabete according to claim 3, which is characterized in that oral formulations are described Preparation be pill, capsule, tablet, powder, granule or oral agents.
6. the arbitrary Chinese medicine composition described in claim 1-6 is preparing the application in treating medicine of quenching one's thirst.
7. a kind of preparation method for the Chinese medicine composition for treating diabete, which is characterized in that include the following steps:
Step 1:Take 10 parts of the Radix Rehmanniae of parts by weight, 10 parts of pueraria lobata, 10 parts of Fructus Corni, 10 parts of Radix Astragali, 5 parts of Radix Ophiopogonis, 5 parts of Poria cocos, north 5 parts of the root of straight ladybell, 5 parts of kadsura longepedunculata, 5 parts of dried orange peel, 5 parts of fructus amomi, 5 parts of Radix Angelicae Sinensis, 5 parts of the membrane of a chicken's gizzard, 5 parts of campanulaceae are respectively put into hot air circulation In baking oven, with 80 DEG C baking 6 it is small when.
Step 2:It crushes, 5 parts of dried drug in step 1 and gypsum is crushed respectively with pulverizer.
Step 3:The medicinal powder crushed is crossed 80 mesh sieves by sieving respectively;
Step 4:Mixing, medicinal powder is uniformly mixed.
Step 5:Molding;
Step 6:Pill, with general preparation method pill;
Step 7:Polishing, until pill surface is smooth consistent.
Step 8:It is dry, pill is uniformly put into heated-air circulation oven, is toasted with 80 DEG C, until dry complete;
Step 9:Ball is selected, underproof pill is picked and is selected;
Step 10:It is filling, qualified pill is dispensed into packaging successively.
CN201711378204.9A 2017-08-15 2017-12-19 A kind of Chinese medicine composition for treating diabete and preparation method thereof Pending CN108114228A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710458167 2017-08-15
CN2017104581676 2017-08-15

Publications (1)

Publication Number Publication Date
CN108114228A true CN108114228A (en) 2018-06-05

Family

ID=62229551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711378204.9A Pending CN108114228A (en) 2017-08-15 2017-12-19 A kind of Chinese medicine composition for treating diabete and preparation method thereof

Country Status (1)

Country Link
CN (1) CN108114228A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103305A (en) * 1993-11-27 1995-06-07 李南山 Diabetes powder and its preparing method
CN1785387A (en) * 2005-11-11 2006-06-14 李永红 Capsnle for treating type II diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103305A (en) * 1993-11-27 1995-06-07 李南山 Diabetes powder and its preparing method
CN1785387A (en) * 2005-11-11 2006-06-14 李永红 Capsnle for treating type II diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王小官等: ""玉液止渴丸治疗消渴病(气阴两虚证) 的临床研究"", 《湖北中医杂志》 *

Similar Documents

Publication Publication Date Title
CN101116503A (en) Health products for reducing blood sugar and method for preparing the same
CN100493572C (en) Composition of medication for treating diabetes
CN103405655A (en) Traditional Chinese medicine composition for reducing blood glucose and preparation method thereof
CN102631595B (en) Medicament for treating II-type diabetes mellitus and preparation method thereof
CN103181560B (en) Health food having effects of life cultivation and health preservation in winter and preparation method thereof
CN102727687B (en) Medicine treating chronic fatigue syndrome and its application
CN106265531A (en) The fresh medicine in a kind of soup side is condensed into corpuscular medicament and preparation method thereof
CN101513492A (en) Chinese medicament for treating diabetes
CN103417846A (en) Hypoglycemic traditional Chinese medicine composition and preparation method thereof
CN100381154C (en) Chinese medicine composition for treating eye disease and preparing method
CN101904916B (en) Medicine for treating diabetes radically and preparation method thereof
CN101607031B (en) Medicated wine for curing and preventing diabetes mellitus, preparation method and application method thereof
CN106420955A (en) Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition
CN105943651A (en) Traditional Chinese medicine composition for treating premature ovarian failure, and application thereof
CN105434802A (en) Pharmaceutical composition for treating diabetes, and preparation method and application thereof
CN108114228A (en) A kind of Chinese medicine composition for treating diabete and preparation method thereof
CN104026568A (en) Health care product composition
CN1977884A (en) Medicinal composition for treating diabetes and its preparing method
CN1943661B (en) A Chinese traditional medicinal composition and its preparation method
CN1253190C (en) Medicine for treating diabetes
CN104173734B (en) A kind of pharmaceutical composition for treating IGR and preparation method thereof
CN102652774A (en) Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method
CN108042710B (en) Traditional Chinese medicine composition for treating qi-yin deficiency and damp-heat internal accumulation type 2 diabetes and application thereof
CN105456734A (en) Traditional Chinese medicine for treating diabetes
CN112206283A (en) Traditional Chinese medicine composition for relieving physical fatigue and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180605

RJ01 Rejection of invention patent application after publication